Jump to content

Ginkgo Bioworks: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
purchase
m corrected tense on their historic status as a private company now they’re public
Tags: Mobile edit Mobile app edit iOS app edit
Line 27: Line 27:
| website = {{URL|ginkgobioworks.com}}
| website = {{URL|ginkgobioworks.com}}
}}
}}
'''Ginkgo Bioworks''' is a [[biotech company]] from the [[United States]] founded in 2009 by scientists from [[Massachusetts Institute of Technology|MIT]] and headed by Jason Kelly. The company specializes in using [[genetic engineering]] to produce [[bacteria]] with industrial applications.<ref>{{cite news |last=Molteni|first=Megan|date=14 September 2017|title=With Designer Bacteria, Crops One Day Could Fertilize Themselves|url=https://www.wired.com/story/with-designer-bacteria-crops-could-one-day-fertilize-themselves/|work=[[Wired (magazine)|Wired]]|access-date=4 December 2017}}</ref><ref>{{cite news |last=Herper|first=Mathew|date=8 June 2016|title=Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry|url=https://www.forbes.com/sites/matthewherper/2016/06/08/boston-startup-raises-100-million-to-use-synthetic-biology-to-design-microbes-for-industry/#511b654f34c4|work=[[Forbes]]|access-date=4 December 2017}}</ref><ref>{{cite news |last=Adams|first=Susan|date=14 September 2017|title=Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer|url=https://www.forbes.com/sites/susanadams/2017/09/14/new-venture-aims-to-make-crops-produce-their-own-nitrogen-fertilizer/#5188255b1db0|work=[[Forbes]]|access-date=4 December 2017}}</ref><ref>{{cite news |last=Weisman|first=Robert|date=29 September 2016|title=Ginkgo Bioworks opens production site for custom cells|url=https://www.bostonglobe.com/business/2016/09/29/ginkgo-bioworks-opens-production-site-for-custom-cells/NOkYPicm7tIusnQRhp0TYL/story.html|work=[[Boston Globe]]|access-date=4 December 2017}}</ref> Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and is one of the world's largest privately held biotech companies.<ref name=":0">{{Cite news|url=https://www.reuters.com/article/us-ginkgobio-fundraising-idUSKBN1WO1U9|title=Ginkgo Bioworks raises $350 million fund for biotech spinouts|date=2019-10-09|work=Reuters|access-date=2019-11-07|language=en}}</ref> In 2019, Gingko was valued at $4.2 billion<ref>{{Cite web |url=https://www.bloomberg.com/news/features/2019-11-06/ginkgo-bioworks-ceo-wants-biology-to-manufacture-physical-goods |title=Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods|website=[[Bloomberg News|Bloomberg]]|access-date=2019-11-07}}</ref> and raised $290 million in September and $350 million in October of that year.<ref name=":0" />
'''Ginkgo Bioworks''' is a [[biotech company]] from the [[United States]] founded in 2009 by scientists from [[Massachusetts Institute of Technology|MIT]] and headed by Jason Kelly. The company specializes in using [[genetic engineering]] to produce [[bacteria]] with industrial applications.<ref>{{cite news |last=Molteni|first=Megan|date=14 September 2017|title=With Designer Bacteria, Crops One Day Could Fertilize Themselves|url=https://www.wired.com/story/with-designer-bacteria-crops-could-one-day-fertilize-themselves/|work=[[Wired (magazine)|Wired]]|access-date=4 December 2017}}</ref><ref>{{cite news |last=Herper|first=Mathew|date=8 June 2016|title=Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry|url=https://www.forbes.com/sites/matthewherper/2016/06/08/boston-startup-raises-100-million-to-use-synthetic-biology-to-design-microbes-for-industry/#511b654f34c4|work=[[Forbes]]|access-date=4 December 2017}}</ref><ref>{{cite news |last=Adams|first=Susan|date=14 September 2017|title=Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer|url=https://www.forbes.com/sites/susanadams/2017/09/14/new-venture-aims-to-make-crops-produce-their-own-nitrogen-fertilizer/#5188255b1db0|work=[[Forbes]]|access-date=4 December 2017}}</ref><ref>{{cite news |last=Weisman|first=Robert|date=29 September 2016|title=Ginkgo Bioworks opens production site for custom cells|url=https://www.bostonglobe.com/business/2016/09/29/ginkgo-bioworks-opens-production-site-for-custom-cells/NOkYPicm7tIusnQRhp0TYL/story.html|work=[[Boston Globe]]|access-date=4 December 2017}}</ref> Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and was one of the world's largest privately held biotech companies,<ref name=":0">{{Cite news|url=https://www.reuters.com/article/us-ginkgobio-fundraising-idUSKBN1WO1U9|title=Ginkgo Bioworks raises $350 million fund for biotech spinouts|date=2019-10-09|work=Reuters|access-date=2019-11-07|language=en}}</ref> valued at $4.2 billion in 2019<ref>{{Cite web |url=https://www.bloomberg.com/news/features/2019-11-06/ginkgo-bioworks-ceo-wants-biology-to-manufacture-physical-goods |title=Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods|website=[[Bloomberg News|Bloomberg]]|access-date=2019-11-07}}</ref> and raised $290 million in September and $350 million in October of that year.<ref name=":0" />


On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with [[Special-purpose acquisition company|SPAC]] Soaring Eagle at a $17.5 billion valuation.<ref>{{Cite news|last=Hussain|first=Niket Nishant, Noor Zainab|date=2021-05-11|title=Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal|language=en|work=Reuters|url=https://www.reuters.com/article/legal-us-gingkgo-m-a-soaring-eagle-idUSKBN2CS2CV|access-date=2021-05-12}}</ref> On 14 May 2021, Ginkgo announced its new ticker for the [[New York Stock Exchange|NYSE]] will be [[DNA]]. The ticker was previously used by [[Genentech]], who stopped using the ticker after they were acquired by [[Roche]].<ref>{{cite web |last1=Ginkgo Bioworks |first1=Austin, Barry, Jason, Reshma, and Tom |title=Taking Ginkgo Public on NYSE:DNA |url=https://www.ginkgobioworks.com/2021/05/14/taking-ginkgo-public-on-nysedna/ |website=Ginkgo Bioworks |publisher=Ginkgo Bioworks |access-date=15 May 2021}}</ref> Trading began September 17, 2021.<ref>{{cite news |last=Leon|first=Riley|date=17 September 2021|title=Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger|url=https://www.cnbc.com/2021/09/17/ginkgo-begins-trading-on-the-nyse-after-completing-spac-merger.html|work=[[CNBC]]|location= |access-date=17 September 2021}}</ref><ref>{{cite press release |url=https://www.businesswire.com/news/home/20210914005748/en/Ginkgo-Bioworks-to-Go-Public-with-Over-1.6-Billion-in-Proceeds |title=Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds |agency=[[Business Wire]] |date=September 14, 2021}}</ref> The largest shareholder (41%) became the investment management firm [[Baillie Gifford]] with a purchase of 167.75 million shares on 31 March 2022.<ref>https://investorplace.com/2022/04/baillie-gifford-just-bought-ginkgo-bioworks-dna-stock-heres-why/</ref>
On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with [[Special-purpose acquisition company|SPAC]] Soaring Eagle at a $17.5 billion valuation.<ref>{{Cite news|last=Hussain|first=Niket Nishant, Noor Zainab|date=2021-05-11|title=Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal|language=en|work=Reuters|url=https://www.reuters.com/article/legal-us-gingkgo-m-a-soaring-eagle-idUSKBN2CS2CV|access-date=2021-05-12}}</ref> On 14 May 2021, Ginkgo announced its new ticker for the [[New York Stock Exchange|NYSE]] will be [[DNA]]. The ticker was previously used by [[Genentech]], who stopped using the ticker after they were acquired by [[Roche]].<ref>{{cite web |last1=Ginkgo Bioworks |first1=Austin, Barry, Jason, Reshma, and Tom |title=Taking Ginkgo Public on NYSE:DNA |url=https://www.ginkgobioworks.com/2021/05/14/taking-ginkgo-public-on-nysedna/ |website=Ginkgo Bioworks |publisher=Ginkgo Bioworks |access-date=15 May 2021}}</ref> Trading began September 17, 2021.<ref>{{cite news |last=Leon|first=Riley|date=17 September 2021|title=Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger|url=https://www.cnbc.com/2021/09/17/ginkgo-begins-trading-on-the-nyse-after-completing-spac-merger.html|work=[[CNBC]]|location= |access-date=17 September 2021}}</ref><ref>{{cite press release |url=https://www.businesswire.com/news/home/20210914005748/en/Ginkgo-Bioworks-to-Go-Public-with-Over-1.6-Billion-in-Proceeds |title=Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds |agency=[[Business Wire]] |date=September 14, 2021}}</ref> The largest shareholder (41%) became the investment management firm [[Baillie Gifford]] with a purchase of 167.75 million shares on 31 March 2022.<ref>https://investorplace.com/2022/04/baillie-gifford-just-bought-ginkgo-bioworks-dna-stock-heres-why/</ref>

Revision as of 22:07, 20 April 2022

Ginkgo Bioworks
Company typePublic
NYSE: DNA
IndustryBiotechnology
Founded2009; 16 years ago (2009) in Boston, Massachusetts, United States
FoundersTom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che
Headquarters
Boston, Massachusetts
,
United States
Key people
Tom Knight
Jason Kelly
Reshma Shetty
Barry Canton
Austin Che
Christina Agapakis
RevenueIncrease US$313.837 Million (Fiscal Year Ended December 31, 2021)[1]
Decrease US$−1.828 Billion (Fiscal Year Ended December 31, 2021)[1]
Decrease US$−1.836 Billion (Fiscal Year Ended December 31, 2021)[1]
Number of employees
~600
Websiteginkgobioworks.com

Ginkgo Bioworks is a biotech company from the United States founded in 2009 by scientists from MIT and headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications.[2][3][4][5] Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and was one of the world's largest privately held biotech companies,[6] valued at $4.2 billion in 2019[7] and raised $290 million in September and $350 million in October of that year.[6]

On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.[8] On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be DNA. The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche.[9] Trading began September 17, 2021.[10][11] The largest shareholder (41%) became the investment management firm Baillie Gifford with a purchase of 167.75 million shares on 31 March 2022.[12]

See also

References

  1. ^ a b c "Ginkgo Bioworks Holdings, Inc. 2021 Form 10-K Report" (PDF). cloudfront.net. 31 December 2021. Retrieved 2 April 2022.
  2. ^ Molteni, Megan (14 September 2017). "With Designer Bacteria, Crops One Day Could Fertilize Themselves". Wired. Retrieved 4 December 2017.
  3. ^ Herper, Mathew (8 June 2016). "Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry". Forbes. Retrieved 4 December 2017.
  4. ^ Adams, Susan (14 September 2017). "Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer". Forbes. Retrieved 4 December 2017.
  5. ^ Weisman, Robert (29 September 2016). "Ginkgo Bioworks opens production site for custom cells". Boston Globe. Retrieved 4 December 2017.
  6. ^ a b "Ginkgo Bioworks raises $350 million fund for biotech spinouts". Reuters. 2019-10-09. Retrieved 2019-11-07.
  7. ^ "Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods". Bloomberg. Retrieved 2019-11-07.
  8. ^ Hussain, Niket Nishant, Noor Zainab (2021-05-11). "Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal". Reuters. Retrieved 2021-05-12.{{cite news}}: CS1 maint: multiple names: authors list (link)
  9. ^ Ginkgo Bioworks, Austin, Barry, Jason, Reshma, and Tom. "Taking Ginkgo Public on NYSE:DNA". Ginkgo Bioworks. Ginkgo Bioworks. Retrieved 15 May 2021.{{cite web}}: CS1 maint: multiple names: authors list (link)
  10. ^ Leon, Riley (17 September 2021). "Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger". CNBC. Retrieved 17 September 2021.
  11. ^ "Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds" (Press release). Business Wire. September 14, 2021.
  12. ^ https://investorplace.com/2022/04/baillie-gifford-just-bought-ginkgo-bioworks-dna-stock-heres-why/


Stub icon

This corporation or company article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Ginkgo_Bioworks&oldid=1083815806"